Skip to content
- Describe the biology and mechanism of action of CAR-T cells in hematological malignancies
- Evaluate the therapeutic efficacy and safety of axicabtagene ciloleucel, tisagenlecleucel and B-cell maturation antigen (BCMA) in patients with selected hematological malignancies
- Assess the efficacy and safety of PD-1 and PD-L1 blockade in combination with brentuximab vedotin and autologous stem cell and allogenic stem cell transplantation in patients with Hodgkin’s lymphoma HL
- Cite the newer treatment options for follicular lymphoma
- Identify the newer treatment options for mantle cell lymphoma
- Apply the novel treatment options for chronic lymphocytic lymphoma
- Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
- Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
- Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia
- Evaluate how compound genotypes are related to novel therapeutic option-based outcomes in patients with acute myeloid leukemia
- Identify response assessment and management of tyrosine kinase inhibitor resistance in the treatment of chronic myeloid leukemia
